The OIG has issued a report entitled “Medicare Payments for Drugs Used To Treat Wet Age Related Macular Degeneration,” which discusses the cost of Lucentis and off-label use of Avastin to treat wet AMD and the potential impact of cost differences on prescribing decisions. The OIG recommends that CMS: (1) establish a national payment code for Avastin when used for the treatment of wet AMD (CMS did not concur at this time), and (2) educate providers about clinical and payment issues related to Lucentis and Avastin (CMS agreed).